Cargando…
TMAO as a potential biomarker and therapeutic target for chronic kidney disease: A review
The gut microbiota and its metabolites have become a hotspot of recent research. Trimethylamine N-oxide (TMAO) metabolized by the gut microbiota is closely related to many diseases such as cardiovascular disease, chronic kidney disease, type 2 diabetes, etc. Chronic kidney disease (CKD) is an import...
Autores principales: | Zixin, Ye, Lulu, Chen, Xiangchang, Zeng, Qing, Fang, Binjie, Zheng, Chunyang, Luo, Tai, Rao, Dongsheng, Ouyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411716/ https://www.ncbi.nlm.nih.gov/pubmed/36034781 http://dx.doi.org/10.3389/fphar.2022.929262 |
Ejemplares similares
-
The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury
por: Liu, Wenhui, et al.
Publicado: (2021) -
Roles of Gut Microbial Metabolites in Diabetic Kidney Disease
por: Fang, Qing, et al.
Publicado: (2021) -
Trimethylamine N-Oxide Exacerbates Renal Inflammation and Fibrosis in Rats With Diabetic Kidney Disease
por: Fang, Qing, et al.
Publicado: (2021) -
The Effects of Ginsenoside Compound K Against Epilepsy by Enhancing the γ-Aminobutyric Acid Signaling Pathway
por: Zeng, Xiangchang, et al.
Publicado: (2018) -
Gut Microbiota-Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic Target
por: Yang, Shengjie, et al.
Publicado: (2019)